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Abstract : This review consists of two parts. In the first part normal mechanisms regulating the pro- 
gression of cells through the cell cycle are briefly reviewed. Besides mitogenic stimulation, cyclin ki- 
nase inhibition, the G1 restriction point and the prb pathway, accuracy of DNA replication and DNA 
repair, the G2 to M transition, apoptosis and the p 53 pathway, proteolytic, in particular ubiquitin - 
dependent mechanisms involved in the initiation of DNA synthesis in the separation of sister chro- 
matids and in the telophase to GO/G1 transition, are discussed. In the second part oncogene and 
tumor suppressor gene products are briefly characterized. Aberrations of cell cycle control mecha- 
nisms associated with cancer are grouped as follows : deregulation of protooncogenes by translo- 
cations juxtaposing protooncogenes to immunoglobulin - or T cell receptor genes; translocations 
producing chimeric proteins unique to cancer cells; inversions and amplifications resulting in over 
expression of regulator genes; and deletions and mutations of tumor suppressor genes. It is em- 
phasized that cancer is the result of a multistep process and that uncontrolled cell production and 
other alterations are, as a rule, late phenomena. (Indian J Pedlatr 1998; 65 : 805o814) 
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Cancer research has contributed signifi- 
cantly to a better understanding of basic 
biological phenomena such as cell division, 
cell differentiation and apoptosis. By study- 
ing pathologic alterations important infor- 
mations on the structure, function and 
regulation of normal cells have been ob- 
tained. In this review the focus will be on 
cell cycle control mechanisms and on con- 
trol deficits associated with cancer. 
Normal Cell Cycle Control Mechanisms 
Cell replication is a complex, well con- 
trolled process ~,2. In each phase of the cell 
cycle, cells that are not prepared to enter 
the next phase are arrested at checkpoints, 
synonymous to blocks controlled by sur- 
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veiUance mechanisms TM. In this way high- 
fidelity replication of the approximately 3 
billion base pairs during the S phase is 
achieved and precise segregation of the 
newly formed chromosomes i guaran- 
teed. 
Mitogenic stimulation 
The initiation of replication depends on 
extracellular signals. Receptors at the cell 
surface bind ligands and activate 
intracellular signal transmission pathways 
to the nucleus. Other ligands may block 
receptors and preclude signal transmis- 
sion. The nucleus of a cell has to receive a 
series of signals within a certain time, be- 
fore replication is initiated. Under sus- 
tained mitogenic stimulation a ceil pre- 
pares itself for replication 5.6. No or insuffi- 
cient preparation occurs, if the cell is dif- 
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ferentiated or if there is a lack of nutrients. 
Cells completely unprepared to divide but 
able to replicate are called GO cells; cells 
partially prepared are in early G1. 
Early G1 is characterized by the fact that 
extracellular mitogenic stimuli can turn on, 
probably by regulating the activity of nu- 
clear transcription factors uch as c-fos, c- 
jun, c-myc and others, the synthesis of cyc- 
lin dependent kinases (cdks). These kinases 
coordinate the transition of cells through 
the 4 phases of the cell cycle G1, S, G2 and 
M ~,4. In order to be active the cdks have to 
complex with cyclins and the holoenzyme 
has to be activated by the cdk activating ki- 
nase CAK, a multi-subunit enzyme consist- 
ing of cyclin H and cdk7 (= MO 15) 7~. CAK 
plays an important role in the regulation of 
transcription. In mammalian cells CAK is 
part of TFIIH, a basal transcription factor 
containing helicase, ATPase and nucle- 
otide-excision repair activities. TFIIH is 
able to phosphorylate the carboxy-terminal 
domain (CTD) of RNA polymerase II 9,1~ 
Mitogens can only stimulate the synthesis 
of D-type cyclins. All other cyclins are syn- 
thesized at specific points during the cell 
cycle independent of extracellular stimuli. 
Cyclin kinase inhibitors 
The formation of active cyclin D -cdks 
can be blocked in many ways. Cdk inhibi- 
tors of the p21 w~ i/c~. p27K~l or p57 r'~ or 
of the p16 xNK4', p15 n~K~, p18 INK~ or p19 ~r~4a 
type bind to the cdks and block either the 
holoenzyme formation with cyclin or the 
phosphorylation at threonin 172, by CAK "z. 
INK4 inhibitors of cdk4 antagonize only 
cyclin D - p21 cn~, p27 KxP~ and p57 raP2 an- 
tagonize cyclin D-and cyclin E-or A-de- 
pendent kinaseslL The p21 c~1 is of particu- 
lar interest since it binds also to the prolif- 
erating cell nuclear antigen (PCNA) which 
is a subunit of the DNA polymerase delta 
enzyme complex 12 
G1 restriction point 
Active cyclin D-cdks phosphorylate he 
retinoblastoma tumor suppressor protein 
prbtL In the unphosphorylated state, the 
prb and the prb-related proteins p107 and 
p130 bind to transcription factors uch as 
E2F and abl and arrest ceils in G1. After 
phosphorylation these transcription factors 
are released and activate genes, the prod- 
ucts of which are required for the transition 
from G1 to S, such as dihydrofolate 
reductase, DNA polymerase alpha, 
thymidine kinase and others ~4. With the 
phosphorylation f the prb the restriction- 
or-checkpoint in G1 is passed and from 
there on, cell replication proceeds without 
additional mitogenic stimulation. 
Both extra-and intraceUular stimulatory 
and inhibitory factors are therefore inte- 
grated before the cell replication machin- 
ery is irrevocably initiated. Once it is 
stared, the cell either divides or dies. 
Initiation of DNA synthesis 
Towards the end of G1 the pre-replication 
complex (pre-RC) is assembled at DNA 
replicating origins 2,1s. This complex repre- 
sents a DNA replication licensing system 
assuring that each DNA sequence is repli- 
cated only one time before chromosome 
segregation 16.The pre-RC is composed of 
the origin recognition complex (ORC), an 
unstable protein called pcdc6, and the 
minichromosome maintenance proteins 
(rectus). 
After phosphorylation f prb, ESF-DP 
heterodimers trigger the expression of cyc- 
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lin E and probably of cyclin A. The activa- 
tion of cyclin E-and cyclin A-cdk2 initiates 
DNA synthesis and inhibits any de novo 
formation of pre-RC ~7. Another cyclin-cdk 
independent kinase, cdc7p-dbf4p (DDK) 
also interacts with components of the pre- 
RC Is. 
After initiation of DNA synthesis, cyclin 
E is inactivated by ubiquitin-dependent 
proteolysis (see below), and the DP  compo- 
nents of heterodimeric ESFs are phophor- 
ylated by cyclin A-cdk2, precluding DNA 
binding of E2Fs n. Cyclin A synthesis pro- 
ceeds throughout S and reaches peak val- 
ues in G2. In early S. cycIin A is associated 
with cdk2, later with cdc2. 
Accuracy of DNA replication and DNA re- 
pair 
The accuracy of DNA replication is 
checked by proofreading functions coupled 
to the DNA polymerization activities. 
TFIIH (see above) plays an important 
role ~s. 
The gene ATM (= ataxia telangiectasia 
muted gene) appears to be involved in 
sensing DNA damage induced by irradia- 
tion and other agents. It activates the TP53 
gene on 17p13 ~2~. p53 acts as a transcrip- 
tion factor 2~ p53 is phoshorylated specifi- 
cally by cyclin A - cdk2 and cyclin B-cdc2, 
but not by cyclin Dl-cdk4 or cyclin E-cdk2. 
Phosphorylation dramatically stimulates 
the binding of p53 to its targets in the 
p21 wAe~/c~ and GADD45 genes m. p53 in- 
duces a block at the G1-S checkpoint and 
slows the progression of cells in S and G2 n. 
p53 also promotes apoptosis ~4. 
Incomplete replication of telomeres is 
counteracted by telomerase, an enzyme 
that may be lost during differentiation. 
Telomeres, GC-rich sequences at the ends 
of each chromosome, are not completely 
copied during DNA synthesis, because 
DNA polymerases require an RNA primer 
to start and because they proceed only in 
the 5' to 3' direction 2s. Without elomerase, 
the potential of a cell to divide is limited 
( cell aging) ~.  
G2toMtransi6on 
The transition from G2 to M is also or- 
chestrated by cyclin-dependent kinase ac- 
tivities, mainly cyclin B-cdc2. Cyclin B is 
first synthesized in late S and peaks in late 
G2 or early M n. Cyclin B-cdc2 is activated 
by phosphorylation at threonine 161. Many 
other factors, e.g. tyrosine kinases and 
phosphatases, control cyclin B-cdc2 activ- 
ity. During mitosis active cyclin B-cdc2 
phosphorylates various substrates, e.g. B- 
type nuclear envelope lamins, at mitosis- 
specific sites in the N-terminal domain. 
Phosphorylation of these sites induces 
lamina depolymerization and nuclear 
membrane dissolution 2s. Cyclin B-cdc2 is 
also involved in the repression of RNA 
polymerase HI~~ 
Ubiquitination, sister chromatid separa- 
tion and telophase to GO~G1 transition 
Mitotic cyclins control the condensation 
of chromosomes, the spindle formation 
and the alignment and attachment of all 
pairs of sister chromatids to the mitotic 
spindle. For the latter process urveillance 
mechanisms exist detecting sister kineto- 
chores which have not been properly 
aligned'.~L These mechanisms block the ac- 
tivation of the anaphase-promoting com- 
plex (APC) or cytosome, a large multisubu- 
nit complex essential for chromosome 
splitting and destruction of M-phase cyc- 
linsZ~L 
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APC and other proteolytic ell cycle en- 
zymes target substrates for 26S proteasome 
degradation by ubiquitination, i.e. assem- 
bling an ubiquitin chain on the substrate. 
Proteolytic degradation of the PDS1 and 
CUT2 proteins is essential for sister chro- 
matid separation, and ubiquitinisation of
M-phase cyclins for deblocking both the 
telophase to G0/G1 transition and the pre- 
RC assembly 17. 
Cell cycle exits 
Cells exit from the cell cycle either by 
differentiation orby necrotic or apoptotic 
cell death. Differentiation is probably re- 
stricted to cells in G0/early G1; death can 
occur in any phase of the cell cycle. Apop- 
tosis is an energy-dependent programmed 
cell death in response to certain stimuli, as- 
sociated with characteristic morphologic 
and biochemical features. Apoptosis can be 
induced by irradiation, chemotherapy, vi-
ral infections, cytotoxic lymphocyte killing, 
and growth factor or hormone withdraw- 
a129s2. Some genes active in the cell cycle 
appear to influence apoptosis ~-s2 e.g. c- 
myc, p53 and prb 24. Apoptosis is another 
mechanism regulating cell production ~.
Aberrations of Cell Cycle Control Mecha- 
nisms Associated with Cancer 
In solid tumors very complex chromo- 
somal anomalies are found, even if prima- 
ry tumours are examined : hyperdiploidy 
to near tetraploidy, structural abnormali- 
ties concerning the centromeric regions, 
amplifications, loss of chromosomes, dele- 
tions and mutations. Mutations in genes 
controlling checkpoints can relieve arrest 
signals and result in continued, uncon- 
trolled progression through the cell cycle. 
A dysreguJation of cell cycle control is vir- 
tu y pathognomic of all cancer cells. 
Oncogenes and Tumor Suppressor Genes 
Oncogenes and tumor suppressor genes 
have been identified by studying cancer- 
causing viruses, by assessing cancer genes 
in tissue cultures, by analyzing genes at 
sites of chromosomal aberration in 
neoplastic ells and by isolating enes for 
cancer-predisposing familial syndromes. 
Oncogene products or products of inap- 
propriate or mutated protooncogene ex- 
pression increase cell production. They 
function as growth factors [e.g. as platelet- 
derived growth factor (PDGF)], growth 
factor eceptors [e.g. for epidermal growth 
factor (EGFR)], proteins involved in signal 
transduction (e.g. upregulating RAS-relat- 
ed signaling pathways), transcription fac- 
tors (e.g. c-myc), or antiapoptosis proteins 
(e.g. BCL-2). Overexpression f oncogenes 
can be the result of gene amplification, 
translocations or inversions. If germ line 
cells are affected, inheritance is dominant u. 
Tumor suppressor gene products, e.g. 
prb, p53, p16 and apoptosis promoting 
proteins uch as bax, reduce or block cell 
production. Tumor suppressor genes can 
be lost or mutated or their products can be 
inactivated, e.g. by viral oncoproteins of
adenovirus (EIA), SV40 (large T antigen) 
and human papilloma-viruses (E6 and E7). 
If germ line cells are affected, inheritance is 
recessive (although some mutants may be 
dominant) ss. 
Chromosomal Aberrations in Cancer and 
Cell Cycle Control 
How frequently structural rearrange- 
ments occur under normal circumstances is 
Vol. 65, No. 6,1998 CELL CYCLE CONTROL AND CANCER 809 
unknown. Inherent genetic instability or 
fragile sites may mediate rearrangements. 
Chromosomal rearrangements are present 
in virtually all malignant cells. A number 
of specific cytogenetic abnormalities have 
been recognized that are closely or even 
uniquely associated with clinically distinct 
subsets of leukemias or solid tumors. 
Translocations Causing Deregulation of 
Gene Expression 
Chromosomal translocations can lead to 
a deregulation fgene expression, either an 
aberrant expression in a tissue that does 
not normally express the gene, or an 
overexpression. Examples are the 
translocations involving immunglobulin 
(Ig) or T-cell receptor (TCR) genes ~s. 
In Burkitt's lymphoma nd B-cen ALL 
the MYC gene at 8q24 is juxtaposed to an 
Ig gene, either the heavy chain gene at 
14q32, the K tight chain gene at 2p12, or the 
X light chain gene at 22q11, by an 8; 14, an 
2; 8 or an 8; 22 translocation, respectively. 
This juxtaposition results in an abnormal 
regulation of MYC expression. The c-myc 
protein localizes to the nucleus and inter- 
acts, by heterodimerization, with MAX and 
other regulators of the myc translational 
system. Transcription from c-myc target 
genes is activated by MYC - MAX and is 
repressed by MAD-MAX or MXI-MAX 
heterodimers 37~. A c-myc activation stimu- 
lates cell proliferation in the absence of 
growth factors. In cells under nutrient dep- 
rivation, c-myc induces apoptosis. In quies- 
cent cells c-myc expression results in acti- 
vation of cyclin E and A, while cyclin D 
may be repressed. In sig:~aling pathways c- 
myc is an esse~ al component, mediating 
transformation by oncoproteins such as 
bcr-abl, CSF-1 receptor tyrosine kinase and 
RAS. 
In follicular lymphoma the BCL2 gene 
on 18q21 is juxtaposed by translocation to
the lg heavy chain gene at 14q32. The 
resulting chimeric protein blocks 
apoptosis ~. 
In B lineage mantle cell lymphomas 
t (11; 14) (q13; q32) puts the lg heavy chain 
inducer on 14q32 into the cyclin D1 locus 
leaving the D1 coding sequences uninter- 
rupted 11. While normal B lymphocytes ex- 
press only cyclins D2 and D3, all lympho- 
ma cells with a t(11 ; 14) ectopically synthe- 
size cyclin D1 (cyclin D1 overexpression in 
other solid tumors : see below~. 
In T-cell disorders, TCR [~-and 8-chain; 
13; or y-chain genes at 14q11; 7q34- 35 and 
7p15, respectively, are juxtaposed by 
translocations to genes encoding transcrip- 
tion factors, such as TALl, LYL1 and 
TAL2~L 
Translocations Producing New Fusion 
(chimeric) Proteins 
Translocations can produce novel fusion 
proteins resulting from the juxtaposition of
coding sequences normally located on dif- 
ferent chromosomes. Fusion profeins are 
only observed in the cancer cells and may 
therefore be important in diagnosis. 
Let~m~s 
Examples for fusion proteins are the 
bcr/abl protein [CML, t (9; 22)], the AML 
1/ETO protein [AML type M2 (M 4), 
t (9; 21)], the PML/RARA protein [AML 
type M 3, t (15, 17)], the. E 2 A/PBX 1 pro- 
tein [pre-B ALL, t (1; 19)] and a number of 
fusion proteins resulting from transloca- 
tions involving the MLL gene at 11 q 23 
[e.g. AML type M 5, t (9; 11)] infant ALL, t 
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(4; 11)] s. The p 210 ~ '~ is located on the cy- 
toplasmic surface of the cell membrane and 
transmits growth-regulatory signals from 
the cell surface receptors via the ras signal 
transduction pathway to the nucleus ~. Ty- 
rosine kinase inhibitors inhibiting the 
growth of cells expressing bcr-abl or relat- 
ed fusion proteins have been described ~.
The core binding factor ot (CBF(z), the nor- 
mal product of AML1, complexes with the 
core binding factor ~ (CBF~) to form a tran- 
scription factor egulating the expression 
of genes critical to myeloid cell growth, dif- 
ferentiation and function such as IL3, GM- 
CSF, MPO and CSF I receptor. The AML1/ 
ETO protein binds to the regulatory re- 
gions of these genes but cannot activate 
their expression ~.  
The PML/RARA protein is released on 
exposure to all-trans-retinoic a id and acti- 
vates retinoic acid responsive gene tran- 
scription inducing differentiation f APL 
cells 3s~. 
E2A, the product of a gene on 19 q 13, 
functions as a transcription factor. The 
gene on lq21 is a homeobox gene. In the 
fusion protein the DNA-binding protein of 
E 2 A is replaced by that of the PBX 1 gene 
which may alter the target genes of the chi- 
meric transcription factor4L 
The MLL gene encodes a transcription 
factor with a zinc finger domain, a DNA 
binding AT-hook, a DNA methyltrans- 
ferase domain and transcription activation 
and repression domains. In all fusion pro- 
teins with the MLL protein, the latter has 
lost the activation domain but retains the 
DNA binding and repression do- 
mains~,~,u,4L 
Solid tumors 
In a large proportion of rhabdomyosar- 
comas at (2; 13) (q35; q14) creating a fusion 
transcription factor involving the PAX 3 
homeobox gene on 2 q 35 and the FKHR 
(forkhead omain) on 13 q 14, was ob- 
served. A variant, t (1; 13) (p36; q14), was 
also described ~~ 
In Ewing's sarcoma, peripheral neu- 
roepithelioma, Askin's tumor, esthesioneu- 
roblastoma and a few meduiloblastomas a 
t (11; 22) (q24; q12) is observed. The trans- 
location results in a chimeric transcription 
factor containing the transactivation do- 
main of the EWS gene (22q12) and the 
DNA binding of the ELl1 gene 
(11(:124) ~-51-s2. 
Inversions and Amplifications Leading to 
Overexpression of Cell Cycle Regulators 
or Protooncogenes 
In parathyroid adenomas an 
i(11)(p15;q13) links cyclin D1 to parathy- 
roid hormone ~. Cyclin D1 (formerly 
PRAD1) encoded on 11q13 (formerly 
CCND1) and CDK4 encoded on 12q13 (to- 
gether with the p53 antagonist MDM2) are 
overexpressed in sarcomas and gliomas ~.  
Amplification of the D1 locus was ob- 
served in almost half of head and neck sq- 
uamous cell carcinomas, in about a third of 
esophageal carcinomas nd in bladder can- 
cers, primary breast cancers, small-cell 
lung cancers and hepatocellular carcino- 
mas ~. Aberrant overexpression f cyclin 
D1 was also seen in sarcomas, colorectal tu- 
mors and melanomas even though D1 gene 
amplification frequencies were low s . In 
mice overexpression f D1 in mammary 
epithelial cells leads to hyperproliferation 
and tumor formation, while animals nul- 
lizygous for D1 show severe defects in 
mammary lobuloalveolar development 
during pregnancy ~.  
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In neuroblastomas predominantly dele- 
tions or rearrangements of the terminal 
portion of lp are found. Loss of heterozy- 
gosity for lp36.2-3, was preseent in 26% of 
primary neuroblastomas sg. In up to a third 
of the cases amplification of the N-MYC 
oncogene is observed ~~ 
Delet ions  and Mutat ions  of Tumor Sup-  
pressor Genes  
Retinoblastoma is the hallmark of a 
tumor due to the loss of a tumor suppres- 
sor gene, the RB1 gene on 13q14. Both 
alleles have to be deleted, before retina 
cells become neoplastic. Inactivation of the 
RB gene is also seen in osteosarcoma, 
carcinoid tumors, small-cell ung cancers 
and invasive bladder cancers ~1. As indi- 
cated previously, the RB product, prb, can 
also be inactivated by viral oncoproteins, 
e.g. human papillomavirus protein E761~2. 
Inactivation of the INK4a locus (on 
9p21) by homozygous deletion, methyla- 
tion of the promotor or point mutation oc- 
curs in approximately 50-60% of gliomas, 
head and neck carcinomas, mesotheliomas 
and T-All, in about 25-50% of bladder and 
pancreas cancer and melanoma s well as 
in oesophagus, gastric, non-small-cell lung, 
renal and prostate cancers s~3. Mutations of 
the INK4a (=CDKN2 or MTS1) gene on 
9p21 resulting in production of inactive 
p16 INK4a, are associated with familial 
melanoma nd are seen in a high propor- 
tion of biliary tract and esophageal carcino- 
mas ~,6s. p16 is frequently detected in pre- 
malignant lesions. It was suggested, there- 
f~re, that p16 inactivation represented an 
early event in tumor development ~. p16 is 
also inactivated by human papillomavirus 
protein E6 e2. Loss of p16 xNK4" might mimic 
cyclin D1 or CDK4 overexpression, both 
leading to hyperphosphorylation and inac- 
tivation of prb. 
The TP53 gene on 17p13 is the most fre- 
quently mutated gene in cancer6L oss of 
TP53 gene alleles, or mutations associated 
with nuclear accumulation of missense 
p53, are characteristically seen in more ad- 
vanced cancers. In patients with colorectal 
cancer, up to 80% were found to have dele- 
tions of 17p13 and the rest had mutations. 
In breast cancer, up to 50% had losses or 
mutations of the p17p13 gene and in many 
other cancers uch as lung and liver, head 
and neck, pancreas, (>esophageal, ovarian, 
endometrial nd cervical cancers as well as 
lymphomas, sarcomas and brain tumors 
nuclear accumulation of missense p53 was 
found by immunostaining. By examining 
the spectrum of p53 mutations in a series of 
tumors, environmental or endogenous fac- 
tors involved in tumorigenesis might be 
recognized ~.
Cancer is the result of a multistep roc- 
ess. If, e.g., chromosomal translocations re- 
sult in a loss of checkpoint control and un- 
controlled proliferation, the increased cell 
production can still be compensated by in- 
creased apoptotic death. Only if a second 
mutation blocks apoptosis, decompensa- 
tion and accumulation of malignant cells 
occurs. As genetic instability increases due 
to diminished cell cycle control, the malig- 
nant cells may acquire additional charac- 
teristics such as invasiveness and de- 
creased rug sensitivity. 
Conclus ions 
This review demonstrates that human 
cancers are often associated with inherited 
or acquired chromosomal berrations lead- 
ing to overexpression or repression of 
genes that play an important role in cell cy- 
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cle replication, di f ferentiat ion and/or  ap- 
optosis. It is also evident,  that important  
decisions, e.g. the ~iggering of cell division 
or of apoptosis, or the induction of cell dif- 
ferentiat ion, are subject to very  complex 
steering mechanisms,,  that take into ac- 
count a mult i tude of extrinsic and intrinsic 
factors. It is not astonishing, therefore, that 
cancer does not result f rom one, but  from 
at least two or more genetic defects or 
events. There is good evidence to suggest 
that cancer develops tepwise, and that un- 
controlled cell proliferation as well as inva- 
siveness and metastat ic spreading or the 
deve lopment  of drug resistance, are, as a 
rule, late phenomena of a long lasting proc- 
ess. It is therefore not surprising, that older 
indiv iduals  are more often affected than 
younger  ones. By extending our  under -  
standing of basic biological phenomena,  
molecular biology and genetics are povid-  
ing bases for more rational diagnostic and 
therapeutic approaches,  by  offering alter- 
natives to actual strategies and by defining 
promis ing targets for new therapeut ic  ef- 
forts. 
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